Kellett Wealth Advisors LLC Has $207,000 Stock Position in Abbott Laboratories (NYSE:ABT)

Kellett Wealth Advisors LLC trimmed its position in Abbott Laboratories (NYSE:ABT) by 17.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,878 shares of the healthcare product maker’s stock after selling 400 shares during the quarter. Kellett Wealth Advisors LLC’s holdings in Abbott Laboratories were worth $207,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in ABT. Fairfield Bush & CO. acquired a new stake in shares of Abbott Laboratories during the first quarter worth approximately $131,000. United Bank boosted its holdings in shares of Abbott Laboratories by 7.2% during the first quarter. United Bank now owns 27,280 shares of the healthcare product maker’s stock worth $3,229,000 after purchasing an additional 1,826 shares during the period. Mackenzie Financial Corp boosted its holdings in shares of Abbott Laboratories by 1.9% during the first quarter. Mackenzie Financial Corp now owns 813,253 shares of the healthcare product maker’s stock worth $96,257,000 after purchasing an additional 15,521 shares during the period. Kinneret Advisory LLC boosted its holdings in shares of Abbott Laboratories by 2.3% during the first quarter. Kinneret Advisory LLC now owns 19,467 shares of the healthcare product maker’s stock worth $2,304,000 after purchasing an additional 436 shares during the period. Finally, Lumature Wealth Partners LLC boosted its holdings in shares of Abbott Laboratories by 636.2% during the first quarter. Lumature Wealth Partners LLC now owns 2,216 shares of the healthcare product maker’s stock worth $262,000 after purchasing an additional 1,915 shares during the period. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Abbott Laboratories news, VP John A. Jr. Mccoy sold 472 shares of the business’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $118.50, for a total value of $55,932.00. Following the transaction, the vice president now owns 18,760 shares of the company’s stock, valued at $2,223,060. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, EVP Andrea F. Wainer sold 12,500 shares of the firm’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $120.00, for a total value of $1,500,000.00. Following the completion of the sale, the executive vice president now owns 78,704 shares of the company’s stock, valued at $9,444,480. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP John A. Jr. Mccoy sold 472 shares of the company’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $118.50, for a total value of $55,932.00. Following the transaction, the vice president now directly owns 18,760 shares in the company, valued at approximately $2,223,060. The disclosure for this sale can be found here. Insiders have sold a total of 56,435 shares of company stock worth $6,451,298 in the last three months. Insiders own 1.10% of the company’s stock.

Abbott Laboratories Price Performance

NYSE ABT traded down $0.63 during trading on Thursday, reaching $105.27. 7,294,151 shares of the company traded hands, compared to its average volume of 5,699,425. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.16 and a current ratio of 1.64. The company has a market cap of $182.66 billion, a price-to-earnings ratio of 32.29, a P/E/G ratio of 2.63 and a beta of 0.74. Abbott Laboratories has a 1-year low of $89.67 and a 1-year high of $121.64. The stock’s 50 day moving average price is $114.42 and its two-hundred day moving average price is $107.59.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Wednesday, April 17th. The healthcare product maker reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.96 by $0.02. Abbott Laboratories had a return on equity of 20.65% and a net margin of 14.27%. The firm had revenue of $9.96 billion during the quarter, compared to analyst estimates of $9.88 billion. During the same period in the prior year, the company posted $1.03 earnings per share. The business’s revenue for the quarter was up 2.2% compared to the same quarter last year. As a group, analysts anticipate that Abbott Laboratories will post 4.62 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 15th. Stockholders of record on Monday, April 15th will be issued a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 2.09%. The ex-dividend date is Friday, April 12th. Abbott Laboratories’s payout ratio is currently 67.48%.

Wall Street Analyst Weigh In

Several brokerages have recently commented on ABT. Citigroup increased their price target on shares of Abbott Laboratories from $126.00 to $128.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Barclays boosted their price target on Abbott Laboratories from $133.00 to $141.00 and gave the stock an “overweight” rating in a research report on Friday, January 26th. Raymond James increased their price objective on Abbott Laboratories from $124.00 to $127.00 and gave the company an “outperform” rating in a report on Thursday, January 25th. TheStreet raised Abbott Laboratories from a “c+” rating to a “b-” rating in a research report on Thursday, December 21st. Finally, Royal Bank of Canada lowered their price target on Abbott Laboratories from $128.00 to $125.00 and set an “outperform” rating on the stock in a report on Thursday. Three equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $121.31.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.